Literature DB >> 17868859

Cardiovascular manifestations of hypereosinophilic syndromes.

Princess U Ogbogu1, Douglas R Rosing, McDonald K Horne.   

Abstract

The hypereosinophilic syndromes (HESs) are characterized by persistent marked eosinophilia (>1500 eosinophils/mm(3)), the absence of a primary cause of eosinophilia (such as parasitic or allergic disease), and evidence of eosinophil-mediated end organ damage. Cardiovascular complications of HES are a major source of morbidity and mortality in these disorders. The most characteristic cardiovascular abnormality in HES is endomyocardial fibrosis. Patients who have an HES also may develop thrombosis, particularly in the cardiac ventricles, but also occasionally in deep veins. Because of the rarity of these disorders, specific guidelines for the management of the cardiac and thrombotic complications of HES are lacking. This article reviews the diagnosis and management of the cardiovascular manifestations of HES.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17868859      PMCID: PMC2048688          DOI: 10.1016/j.iac.2007.07.001

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN: 0889-8561            Impact factor:   3.479


  103 in total

1.  Evaluation of cardiac involvement in hypereosinophilic syndrome: complementary roles of transthoracic, transesophageal, and contrast echocardiography.

Authors:  Rajesh Shah; Karthik Ananthasubramaniam
Journal:  Echocardiography       Date:  2006-09       Impact factor: 1.724

2.  Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report.

Authors:  Amy D Klion; Bruce S Bochner; Gerald J Gleich; Thomas B Nutman; Marc E Rothenberg; Hans-Uwe Simon; Michael E Wechsler; Peter F Weller
Journal:  J Allergy Clin Immunol       Date:  2006-05-03       Impact factor: 10.793

3.  Increased heparin requirement with hypereosinophilic syndrome.

Authors:  S T Hanowell; Y D Kim; V Rattan; T E MacNamara
Journal:  Anesthesiology       Date:  1981-10       Impact factor: 7.892

4.  The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory states.

Authors:  Jian-Guo Wang; Shawn A Mahmud; Jacob A Thompson; Jian-Guo Geng; Nigel S Key; Arne Slungaard
Journal:  Blood       Date:  2005-09-15       Impact factor: 22.113

5.  Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy.

Authors:  G Palareti; N Leali; S Coccheri; M Poggi; C Manotti; A D'Angelo; V Pengo; N Erba; M Moia; N Ciavarella; G Devoto; M Berrettini; S Musolesi
Journal:  Lancet       Date:  1996-08-17       Impact factor: 79.321

6.  Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Jack Hirsh; Robert Raschke
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

7.  Left ventricular thrombus following acute myocardial infarction: a prospective serial echocardiographic study of 96 patients.

Authors:  C A Visser; G Kan; K I Lie; D Durrer
Journal:  Eur Heart J       Date:  1983-05       Impact factor: 29.983

8.  Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?

Authors:  U Priglinger; G Delle Karth; A Geppert; C Joukhadar; S Graf; R Berger; M Hülsmann; S Spitzauer; I Pabinger; G Heinz
Journal:  Crit Care Med       Date:  2003-05       Impact factor: 7.598

9.  Eosinophil cationic granule proteins impair thrombomodulin function. A potential mechanism for thromboembolism in hypereosinophilic heart disease.

Authors:  A Slungaard; G M Vercellotti; T Tran; G J Gleich; N S Key
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

10.  The natural history of left ventricular thrombus in myocardial infarction: a rationale in support of masterly inactivity.

Authors:  P Nihoyannopoulos; G C Smith; A Maseri; R A Foale
Journal:  J Am Coll Cardiol       Date:  1989-10       Impact factor: 24.094

View more
  84 in total

1.  Spontaneous fusion between cancer cells and endothelial cells.

Authors:  K Mortensen; J Lichtenberg; P D Thomsen; L-I Larsson
Journal:  Cell Mol Life Sci       Date:  2004-08       Impact factor: 9.261

Review 2.  Cardiac manifestation of the hypereosinophilic syndrome: new insights.

Authors:  T Kleinfeldt; C A Nienaber; S Kische; I Akin; R G Turan; T Körber; H Schneider; H Ince
Journal:  Clin Res Cardiol       Date:  2010-03-24       Impact factor: 5.460

3.  Hypereosinophilic syndrome with cardiac involvement in a pregnant patient with multiple sclerosis.

Authors:  Amir Darki; Preeti P Kodali; John P McPheters; Harkiran Virk; Minesh R Patel; William Jacobs
Journal:  Tex Heart Inst J       Date:  2011

4.  MDCT evaluation of cardiac involvement in hypereosinophilic syndrome: differentiating mural thrombus, infarcted, and noninfarcted myocardium by delayed-phase scanning.

Authors:  Chuan-Han Chen; I-Chen Tsai; Sheng-Ling Jan; Wei-Lin Tsai; Clayton Chi-Chang Chen
Journal:  Tex Heart Inst J       Date:  2011

Review 5.  Advances in diagnosis and treatment of eosinophilia.

Authors:  Javed Sheikh; Peter F Weller
Journal:  Curr Opin Hematol       Date:  2009-01       Impact factor: 3.284

6.  Hypereosinophilic syndrome associated with ulcerative colitis presenting with recurrent Loeffler's endocarditis and left ventricular thrombus treated successfully with immune suppressive therapy and anticoagulation.

Authors:  Srikanth Koneru; George Koshy; Colin Sharp; Alhossain A Khalafallah
Journal:  BMJ Case Rep       Date:  2013-09-05

Review 7.  Eosinophils and disease pathogenesis.

Authors:  Praveen Akuthota; Peter F Weller
Journal:  Semin Hematol       Date:  2012-04       Impact factor: 3.851

Review 8.  Evaluation and differential diagnosis of marked, persistent eosinophilia.

Authors:  Rojelio Mejia; Thomas B Nutman
Journal:  Semin Hematol       Date:  2012-04       Impact factor: 3.851

9.  Macrophages and cardiac fibroblasts are the main producers of eotaxins and regulate eosinophil trafficking to the heart.

Authors:  Nicola L Diny; Xuezhou Hou; Jobert G Barin; Guobao Chen; Monica V Talor; Julie Schaub; Stuart D Russell; Karin Klingel; Noel R Rose; Daniela Čiháková
Journal:  Eur J Immunol       Date:  2016-10-25       Impact factor: 5.532

10.  Eosinophilic endomyocarditis combined with pericardial and pleural effusion.

Authors:  Sung-Hye You; Soon Jun Hong; Chul Min Ahn; Do-Sun Lim
Journal:  Korean Circ J       Date:  2009-12-30       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.